Ibogaine and Pre-Existing Heart Conditions: Why QTc Screening Comes First

Definition box

Definition: Ibogaine and pre-existing heart conditions addresses why people with known cardiac disease, baseline prolonged QTc, long QT syndromes, heart-failure history, prior arrhythmia, or QT-prolonging medication regimens are often excluded—or require specialist review that may still end in a hard stop—before physician-supervised IV ibogaine infusion (intravenous psychoactive ibogaine with continuous monitoring). Ibogaine can prolong the QTc interval and raise risk for life-threatening arrhythmia. Evidence gap: Landmark open-label cardiac observations such as Knuijver et al. (*Addiction*, 2021) reflect oral ibogaine HCl; Cherian/MISTIC (*Nature Medicine* 2024) used oral ibogaine + IV magnesium support—not proof that psychoactive IV is safe in cardiac disease. Support IV ≠ psychoactive IV. Ibogaine is U.S. Schedule I and not FDA-approved. Programs discussed here are provisionally available in Mexico. No cure claims. No DIY clearance.

Quotable answer (56 words)

Pre-existing heart conditions often contraindicate or heavily restrict ibogaine exposure because ibogaine can prolong QTc and increase arrhythmia risk. IV ibogaine infusion requires physician supervision and continuous cardiac monitoring. Most published QTc observations still reflect oral ibogaine HCl. It is not FDA-approved. Unsupervised use is dangerous; individual clearance belongs to clinicians.

The non-negotiable frame

If you remember one sentence from this page:

> Hopeful addiction or veteran headlines do not override cardiac anatomy.

Marketing that says “we’ll watch your heart a little” while enrolling unscreened candidates with known long QT is a red flag, not a feature.

Canonical safety home: /safety-and-screening · Broader exclusions: /blog/ibogaine-contraindications · ECG questions to ask: /blog/ibogaine-ecg-checklist.

What QTc prolongation means in plain language

The QT interval on an ECG reflects ventricular recovery. Corrected for heart rate (QTc), excessive prolongation increases risk for torsades de pointes, which can degenerate into fatal arrhythmia. Ibogaine-related pharmacology has been discussed in connection with delayed repolarization (including hERG-related mechanisms in scientific conversation).

Oral-route teaching signal (label every time)

Knuijver et al. (*Addiction*, 2021): open-label oral ibogaine HCl (10 mg/kg) in 14 opioid-dependent patients—reported findings included large average QTc prolongation, a substantial fraction exceeding 500 ms in that sample, bradycardia/BP decreases, and severe transient ataxia. No torsades in n=14 does not equal no risk.

Route changes pharmacokinetics; it does not authorize skipping ECG for IV protocols.

Pre-existing conditions commonly treated as high concern

Educational themes—not an exhaustive algorithm and not personal advice:

Often potential hard stops / cardiology-first territory

• Congenital or acquired long QT
• Baseline prolonged QTc on pre-care ECG
• Recent myocardial infarction, unstable angina
• Decompensated heart failure
• Clinically significant arrhythmia history (context-dependent)
• Uncorrected severe hypokalemia or hypomagnesemia
• Inability to complete continuous telemetry or emergency transfer

Medication-related cardiac risk amplifiers

• Concurrent QT-prolonging drugs without specialist plan
• Complex psychotropic / antibiotic / antiemetic / methadone risk stacks
• Unreviewed stimulants or polysubstance combinations

“I feel fine” is not clearance

Absence of chest pain today does not equal safe repolarization reserve under ibogaine exposure.

IV magnesium myths in cardiac candidates

MISTIC / Cherian et al. (*Nature Medicine* 2024) used IV magnesium with oral ibogaine in a carefully screened veteran cohort. That is a support / coadministration story inside an open-label design—not a cardiac-disease license and not psychoactive IV ibogaine proof.

IV Mg ≠ defibrillator. IV Mg ≠ permission to ignore long QT.

MISTIC spoke: /blog/stanford-ibogaine-mistic · Support IV teaching: /blog/electrolytes-support-iv-vs-psychoactive-iv.

Veterans, TBI/PTSD interest, and cardiac honesty

Veteran hope after open-label coverage is understandable. It still does not convert oral+Mg signals into IV cardiac safety for everyone with ischemic disease or pacemaker questions. TBI/PTSD pages: /blog/ibogaine-for-tbi-veterans · /ibogaine-for-ptsd · Right-to-Try literacy: /blog/ibogaine-right-to-try-veterans.

What ethical programs do before saying yes—or no

1. Medical history focused on cardiac events and family sudden-death clues
2. Medication reconciliation for QT risk
3. Baseline ECG with QTc interpretation by qualified clinicians
4. Electrolytes and repletion plan when indicated
5. Continuous monitoring capability sized to a prolonged risk window
6. Written emergency pathway
7. Cultural willingness to refund/refuse rather than dose anyway

If a “clinic near me” ad skips these, leave: /blog/ibogaine-clinic-near-me · /blog/cheap-ibogaine-clinic-red-flags · /blog/how-to-choose-an-ibogaine-clinic.

Liver and heart together

Hepatic impairment and metabolic interactions can compound risk management complexity. Liver literacy: /blog/ibogaine-and-liver-health. Neither organ system page replaces the other.

Mexico provisional does not reduce arrhythmia risk

Programs discussed on this site are provisionally available in Mexico, not as FDA-approved U.S. cardiology infusion centers. Flying south does not shorten QTc. Geography honesty: /blog/ibogaine-mexico-medical-vs-tourism · Legal education: /blog/is-ibogaine-legal-us.

Mosca et al. systematic review: limited RCTs; cardiotoxicity concerns—exactly why this page exists.

Bradycardia, blood pressure, and the monitoring window

Open-label oral observations have included bradycardia and blood-pressure decreases alongside QTc signals. For candidates with conduction disease, syncope history, or antihypertensive complexity, that combination matters: a prolonged observation window is not spa theater—it is risk management. Programs sized like a 40-minute ketamine drip are operationally mismatched to ibogaine’s cardiac story (/blog/ibogaine-vs-ketamine-for-addiction · /blog/ibogaine-program-duration).

Implantable devices and “special case” shopping

People with pacemakers, ICDs, or prior ablations sometimes hunt for a clinic that will “still take me.” Device presence does not automatically equal clearance, nor does it automatically equal universal exclusion—cardiology-owned judgment does. What is never appropriate: forum advice to disable device alerts, skip interrogation, or hide device history to pass intake. Concealment is a safety failure.

Addiction urgency vs cardiology veto

Opioid withdrawal panic can pressure families to override a cardiologist’s no. Ethical framing: a declined ibogaine candidate can still pursue guideline-concordant withdrawal management and MOUD pathways. Ibogaine interest is not a moral trump card over arrhythmia risk (/blog/ibogaine-withdrawal-vs-detox · /ibogaine-for-addiction).

Soft CTA

If you have a heart-history question, start with screening education—not deposits. Review /safety-and-screening, then request a confidential screening consult via /apply only with the understanding that cardiac findings may mean no. That refusal is ethical care.

FAQ

Can I receive IV ibogaine if I have a heart condition? Often high-concern or exclusionary. Only a licensed clinician reviewing your records/ECG can decide. Many serious programs will say no.

Does a normal stress test clear me? Not automatically. QTc-specific diligence and medication review still matter.

Is IV safer than oral for cardiac patients? Do not assume. Controlled psychoactive-IV evidence is sparse; oral QTc signals still discipline caution.

Does magnesium fix ibogaine heart risk? IV magnesium support does not eliminate arrhythmia risk or replace exclusions.

Are deaths from ibogaine only in unsupervised settings? Adverse cardiac events have been discussed across heterogeneous settings. Medical supervision reduces—not erases—risk.

Is ibogaine FDA-approved for any cardiac or addiction use? No. Schedule I; not FDA-approved.

Should I stop heart medications to qualify? Never self-stop cardiac meds. Discuss only with your clinicians.

Where next? /safety-and-screening → /apply.

Medical disclaimer

Educational cardiology-literacy page only—not a personal clearance, not ECG interpretation, and not medical advice. Ibogaine can cause life-threatening arrhythmia and is not FDA-approved. Unsupervised use is dangerous. Soft CTAs: /safety-and-screening, /apply.

Sources (selected)

1. Knuijver T. et al. *Addiction*. 2021 — oral ibogaine HCl; QTc observational findings.
2. Cherian K.N. et al. *Nature Medicine*. 2024 — open-label oral ibogaine + IV magnesium; not IV-psychoactive cardiac-safety proof.
3. Mosca A. et al. *Current Neuropharmacology* — systematic review; limited RCTs; cardiotoxicity concerns.
4. 21 CFR 1308.11 — ibogaine Schedule I (United States).